PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för (R)-lisofylline. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

9 hits

Bibliografisk träff 2018-10-06

Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus.

Italiya KS, Mazumdar S, Sharma S, Chitkara D, Mahato RI, Mittal A.

Nanomedicine · research support, non-u.s. gov't; journal article · DOI 10.1016/j.nano.2018.09.014

Bibliografisk träff 2017-07-20

PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response.

Świerczek A, Wyska E, Baś S, Woyciechowska M, Mlynarski J.

Naunyn Schmiedebergs Arch Pharmacol · research-article; journal article · DOI 10.1007/s00210-017-1406-z

Bibliografisk träff 2015-02-08

Physiologically based modeling of lisofylline pharmacokinetics following intravenous administration in mice.

Wyska E, Świerczek A, Pociecha K, Przejczowska-Pomierny K.

Eur J Drug Metab Pharmacokinet · research-article; journal article · DOI 10.1007/s13318-015-0260-y

Bibliografisk träff 2005-01-01

Lisofylline: a potential lead for the treatment of diabetes.

Yang Z, Chen M, Nadler JL.

Biochem Pharmacol · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.bcp.2004.08.012

Bibliografisk träff 2003-05-01

The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice.

Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL.

Pancreas · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1097/00006676-200305000-00021

Bibliografisk träff 2002-08-01

The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice.

Yang ZD, Chen M, Wu R, McDuffie M, Nadler JL.

Diabetologia · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1007/s00125-002-0901-y

Bibliografisk träff 2002-01-01

Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome.

Författaruppgift saknas

Crit Care Med · clinical trial; research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/00003246-200201000-00001

Bibliografisk träff 1999-05-01

Effects of lisofylline on hyperoxia-induced lung injury.

George CL, Fantuzzi G, Bursten S, Leer L, Abraham E.

Am J Physiol · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1152/ajplung.1999.276.5.l776

Bibliografisk träff 1994-04-01

CT-1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo.

Rice GC, Rosen J, Weeks R, Michnick J, Bursten S, Bianco JA, Singer JW.

Shock · journal article · DOI 10.1097/00024382-199404000-00003